162 related items for PubMed ID: 8979286
1. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height.
Jääskeläinen J, Voutilainen R.
Pediatr Res; 1997 Jan; 41(1):30-3. PubMed ID: 8979286
[Abstract] [Full Text] [Related]
2. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W, Schmidt H, Schwarz HP.
Horm Res Paediatr; 2011 Jan; 75(1):32-7. PubMed ID: 20714115
[Abstract] [Full Text] [Related]
3. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A.
Eur J Endocrinol; 1997 Feb; 136(2):188-95. PubMed ID: 9116914
[Abstract] [Full Text] [Related]
4. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J, Aldridge S, Thomas M, Cheetham T.
J Pediatr Endocrinol Metab; 2018 Sep 25; 31(9):1019-1022. PubMed ID: 30173205
[Abstract] [Full Text] [Related]
5. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W, Schwarz HP.
Horm Res Paediatr; 2011 Sep 25; 75(4):264-8. PubMed ID: 21196707
[Abstract] [Full Text] [Related]
6. [Growth and adult height in patients with congenital adrenal hyperplasia].
Kolousková S, Zemková D, Snajderová M, Lebl J.
Cas Lek Cesk; 1995 Nov 01; 134(21):689-91. PubMed ID: 8556761
[Abstract] [Full Text] [Related]
7. Long-term Growth in Congenital Adrenal Hyperplasia.
Maheshwari A, Khadilkar V, Gangodkar P, Khadilkar A.
Indian J Pediatr; 2019 Feb 01; 86(2):154-158. PubMed ID: 30097840
[Abstract] [Full Text] [Related]
8. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia.
Bomberg EM, Addo OY, Kyllo J, Gonzalez-Bolanos MT, Ltief AM, Pittock S, Himes JH, Miller BS, Sarafoglou K.
J Pediatr; 2015 Mar 01; 166(3):743-50. PubMed ID: 25557963
[Abstract] [Full Text] [Related]
9. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SM, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM.
Arch Dis Child; 2002 Aug 01; 87(2):139-44. PubMed ID: 12138066
[Abstract] [Full Text] [Related]
10. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C.
Clin Endocrinol (Oxf); 2002 Nov 01; 57(5):669-76. PubMed ID: 12390343
[Abstract] [Full Text] [Related]
11. Gender dichotomy in long term growth trajectories of children with 21-hydroxylase deficiency congenital adrenal hyperplasia.
Patel L, Chandrashekhar SR, Gemmell I, O'Shea E, Jones J, Banerjee I, Amin R, Clayton P.
Horm Res Paediatr; 2011 Nov 01; 75(3):206-12. PubMed ID: 20962509
[Abstract] [Full Text] [Related]
12. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP, Winter A, Stolecke H.
Klin Padiatr; 1997 Nov 01; 209(2):71-7. PubMed ID: 9113619
[Abstract] [Full Text] [Related]
13. Adult height of subjects with nonclassical 21-hydroxylase deficiency.
Eyal O, Tenenbaum-Rakover Y, Shalitin S, Israel S, Weintrob N.
Acta Paediatr; 2013 Apr 01; 102(4):419-23. PubMed ID: 23298233
[Abstract] [Full Text] [Related]
14. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
Muirhead S, Sellers EA, Guyda H, Canadian Pediatric Endocrine Group.
J Pediatr; 2002 Aug 01; 141(2):247-52. PubMed ID: 12183722
[Abstract] [Full Text] [Related]
15. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood.
Yu AC, Grant DB.
Acta Paediatr; 1995 Aug 01; 84(8):899-903. PubMed ID: 7488814
[Abstract] [Full Text] [Related]
16. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
Hoepffner W, Kaufhold A, Willgerodt H, Keller E.
Horm Res; 2008 Aug 01; 70(1):42-50. PubMed ID: 18493149
[Abstract] [Full Text] [Related]
17. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study.
Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, Kovács J, Waldhauser F, Frisch H, MEWPE-CAH Study Group.
Horm Res; 2001 Aug 01; 55(4):161-71. PubMed ID: 11598369
[Abstract] [Full Text] [Related]
18. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N, Di Maio S, Salerno M, Argenziano A, Franzese A, Tenore A.
Horm Res; 1997 Aug 01; 47(1):17-22. PubMed ID: 9010713
[Abstract] [Full Text] [Related]
19. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.
Roche EF, Charmandari E, Dattani MT, Hindmarsh PC.
Clin Endocrinol (Oxf); 2003 May 01; 58(5):589-96. PubMed ID: 12699440
[Abstract] [Full Text] [Related]
20. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2007 May 01; 92(5):1635-9. PubMed ID: 17299071
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
